Today: September 30, 2016, 12:02 pm

Pharmaceutical anti-counterfeit drugs market forecast to be valued at US$1.1Bn in 2014
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2014-2024 - a new market research report on 2014-03-20 11:05:04
The worldwide pharmaceutical anti-counterfeit drugs technologies market forecast to be driven by government mandates during the period 2012 to 2017. By the end of 2014, the worldwide drugs anti-counterfeiting market is forecast to be valued at US$1.1 billion. The rising concerns over counterfeiting drugs will drive increased investment in the authentication and verification solutions which are focused on improving drug security.

The majority of countries lack the appropriate legislation to govern the manufacture, distribution, export and import pharma products at the appropriate level to protect against counterfeits. The WHO esimates that over 200,000 deaths annually are sourced from counterfeit drug intake and as a result could be prevented.

Poor coordination between drug regulatory agencies, healthcare providers, law enforcement bodies, and the consumers all contribute to the prevalence of counterfeiting activities in some developing regions. Therefore, close co-operation between manufacturers, pharmaceutical wholesalers, pharmacies, and the relevant authorities is needed to ensure a high degree of safety for pharma products.

The pharmaceutical anti-counterfeiting technologies market will witness significant opportunities for growth in the coming decade. An array of innovative and cost-effective anti-counterfeiting solutions is expected to be launched into the market by 2017. These innovative technologies, coming particularly from the fast growing radio-frequency identification (RFID) sector, will help in driving revenue growth in this market. We also expect innovations in the RFID sector to propel sales up significantly in the emerging economies as these technologies begin to gain market penetration

Between 2012 and 2017, growth in the market will be fuelled by government mandates that will require the unique serialisation of pharmaceutical products. In the US, these mandates have been proposed in California and Florida and there is a debate for it to be implemented nationwide. Growth will also be driven by the rising publicity given to technological solutions for track-and-trace purposes. Pharmaceutical companies are coming to the realisation that drug counterfeiting poses a significant danger to their brand´s reputation and patient safety.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 523 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.